EDGAR·FLOW

TELA Bio, Inc. — Form 8-K

Filed October 5, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
TELA Bio announced FDA 510(k) clearance on October 5, 2026 for Liora, a fully resorbable surgical mesh device for soft tissue reinforcement. Liora is the company's first fully resorbable synthetic product designed and manufactured in-house at its ISO 8 certified cleanroom in Malvern, PA. No financial impact, timeline, or commercial milestones were specified in the filing.
Why this rating

Regulatory milestone expanding product portfolio in core market; material for $76.8M company, but execution risk and revenue timing unclear.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$1.14 ▼ 1.72%
at our read · unknown
$1.16
+10 min · unknown
$1.16 ▼ 0.43%
+30 min · unknown
$1.16 ▼ 0.17%
+1 hr · unknown
$1.14 ▼ 1.72%
+4 hrs · unknown
$1.15 ▼ 0.86%

The stock had already moved +1.75% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ TELA · stock on Yahoo Finance ↗

See more from October 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.